Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma
Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma
复制标题
DOI：
10.1016/j.humpath.2015.07.023
复制
发表时间：
2015-12-01
期刊：
影响因子：
3.3
通讯作者：
Peng, Yan
中科院分区：
文献类型：
--
作者：
Dang, Daniel N.;Raj, Ganesh;Peng, Yan
PELP 1是一种新型的核激素受体的辅助调节因子，并参与驱动乳腺癌和增强转移潜力的作用。PELP 1蛋白表达和PELP 1在三阴性乳腺癌（TNBC）中的潜在作用尚未得到很好的表征。我们通过免疫组织化学研究了PELP 1在人类组织中原发性和转移性三阴性肿瘤中的表达，并将其表达与TNBC的新型诊断标志物GATA结合蛋白3（GATA 3）进行了比较。我们检测了70例原发性TNBC病例中PELP 1和GATA 3的表达，发现PELP 1的表达频率显著高于GATA 3（96%对46%; P < .0001）。PELP 1表达的平均程度评分也显著高于GATA 3的表达（3.87 +/- 0.07对0.91 +/- 0.15; P <0.0001）。PELP 1的染色强度比GATA 3强。此外，在成对的原发性和转移性TNBC病例中，PELP 1免疫反应性始终保持不变（100%）。PELP 1在转移性三阴性肿瘤中的表达频率（100%）高于GATA 3在相同肿瘤中的表达频率（40%）（P <0.0001）。这些发现表明，对于TNBC，PELP 1是比GATA 3敏感得多的标志物。在适当的情况下，PELP 1可能对转移性TNBC具有诊断实用性，例如在原发性TNBC对GATA 3、乳房珠蛋白和GCDFP-15呈阴性的情况下的原发性TNBC病史。在大多数情况下，PELP 1的弥漫性和强的核免疫反应性表明PELP 1可能是治疗TNBC的分子靶点。我们希望这项研究将为PELP 1在TNBC中的作用提供见解。(C)2015 Elsevier Inc. All rights reserved.
PELP1 is a novel coregulator of nuclear hormone receptors and is implicated in playing a role in driving breast cancer and enhancing metastatic potential. The PELP1 protein expression and potential role of PELP1 in triple-negative breast carcinoma (TNBC) have not been well characterized. We investigated PELP1 expression by immunohistochemistry in primary and metastatic triple-negative tumors in human tissues and compared its expression with GATA-binding protein 3 (GATA3), a novel diagnostic marker for TNBC. We examined the expression of PELP1 and GATA3 in 70 primary TNBC cases and found that PELP1 had a significantly higher frequency of expression compared to GATA3 (96% versus 46%; P < .0001). The mean extent score of expression of PELP1 was also significantly higher than GATA3's expression (3.87 +/- 0.07 versus 0.91 +/- 0.15; P < .0001). PELP1 had stronger staining intensity than GATA3. Furthermore, PELP1 immunoreactivity was consistently maintained in paired primary and metastatic TNBC cases (100%). The frequency of PELP1 expression (100%) in metastatic triple-negative tumors was higher than that of GATA3 (40%) in the same tumors (P < .0001). These findings indicate that PELP1 is a much more sensitive marker than GATA3 for TNBCs. PELP1 may have diagnostic utility for metastatic TNBC in appropriate settings, such as history of primary TNBC in cases where the primary is negative for GATA3, mammaglobin, and GCDFP-15. The diffuse and strong nuclear immunoreactivity of PELP1 in most cases suggests that PELP1 may be a molecular target for the treatment of TNBC. We hope that this study will provide insights into the role of PELP1 in TNBC. (C) 2015 Elsevier Inc. All rights reserved.